Sotatercept Endorsed for PAH by ICER
Drug's novel mechanism of action raises hopes of disease-modifying activity, but long-term cost-effectiveness rests on improvement in functional status.
United States San Francisco Greg Curfman Marc Simon Effectiveness Public Advisory Council World Health Organization
Source: medscape.com